About Viewray

Meet Our Team

At ViewRay®, our vision is clear—we’re dedicated to giving clinicians new and better ways to treat cancer with radiation therapy. Meet our industry leaders committed to innovation excellence.

Scott Drake

President and Chief Executive Officer

Scott Drake joined ViewRay as President and CEO as of July 2018. He served as President and Chief Executive Officer of Spectranetics (NASDAQ: SPNC) from 2011 to 2017. Under Drake’s leadership, revenue grew from $117.9 million in 2010 to $245.9 million in 2015. Drake’s engineering of the 2014 acquisition of AngioScore Inc. and the 2015 acquisition of the Stellarex™ drug-coated balloon platform broadened the company’s portfolio for delivering clinical solutions for complex cardiovascular conditions and paved the way for future growth. Prior to joining Spectranetics, Drake served as Senior Vice President, Operations, of DaVita, Inc. (NYSE: DVA), a leading U.S. provider of kidney care and dialysis. His operations generated more than $6 billion of revenue, or about 20% of DaVita’s total revenue. Previously, Drake spent 17 years in several leadership positions within numerous health care business units at Covidien. From 2006 to 2009, Drake was Global Business Unit President, Respiratory and Monitoring Solutions, a $1.5 billion business with 8,000 employees. Drake was named an EY 2014 Entrepreneur Of The Year™. He is Chairman of the Boards of AtriCure (NASDAQ: ATRC) and Just Right Surgical and serves on the board of directors of the Medical Device Manufacturers Association (MDMA). He earned a BS in Business Administration from Miami University of Ohio.

Robert McCormack

Senior Vice President, General Counsel and Corporate Secretary

Robert McCormack joined ViewRay as Senior Vice President, General Counsel and Corporate Secretary in August 2018. He has worked in the medical device and IT industries since 2008. Prior to that, Mr. McCormack worked in private practice in Denver, Colorado, where he focused on corporate, securities, mergers and acquisitions, and general business matters. Mr. McCormack holds a JD from the University of Denver, College of Law and a BS in Finance from Metropolitan State University of Denver.

James F. Dempsey, PhD

Chief Scientific Officer

Company founder and inventor of the ViewRay technology, Jim Dempsey guides the scientific and technical aspects of the MRIdian system’s development. Dempsey holds a PhD in nuclear chemistry from Washington University. He is a board-certified medical physicist and former associate professor of radiation oncology at the University of Florida.

Shahriar (Shar) Matin

Chief Operating Officer

Shar Matin joined ViewRay as Chief Operating Officer (COO) as of July 2018. He served as Chief Operating Officer of Spectranetics from 2014 to 2017. Following the closing of AngioScore Inc. in 2014 and Stellarex™ in 2015, Matin became the President of the AngioScore subsidiary and leads Spectranetics’ drug-coated balloon programs. At Spectranetics, Matin started his career as Managing Director of Europe, Russia and the Middle East in 2007. He was promoted to Vice President and Managing Director, International, in 2008. In 2010, He became Senior Vice President of Operations, Product Development and International, and in 2012, he became Senior Vice President of Operations, Business Development and International. Before joining Spectranetics, Matin was the Business Unit Director for Boston Scientific’s cardiac rhythm management operations in China and served in several commercial and engineering roles at Guidant Corporation. Mr. Matin serves on the board of directors of the Fitzsimons Redevelopment Authority in Aurora, Colorado Mr. Matin earned a BS in Mechanical Engineering from the University of California, Berkeley, with honors, and an MBA from Harvard Business School.

Ajay Bansal

Chief Financial Officer

Mr. Bansal brings to ViewRay nearly 30 years of life sciences industry experience, spanning the areas of finance, commercialization, strategic planning and business development. Since 2003, Mr. Bansal has served as CFO of various life sciences companies, raising over $1 billion of capital. Most recently, he served as CFO of Onconova Therapeutics, where he led the company’s initial public offering in 2013. Prior to that, Mr. Bansal served as CFO of Complete Genomics, where he led the company’s initial public offering in 2010. Previously, Mr. Bansal was a partner at Mehta Partners, LLC. where he provided strategic advisory services to the firm’s biotechnology and pharmaceutical clients. Earlier in his career, Mr. Bansal worked in strategy, sales and marketing for Novartis Pharmaceuticals and held positions with leading consulting firms, including McKinsey & Company. He received Masters degrees in both management and operations research from Northwestern University.

Martin Fuss, MD

Chief Medical Officer

Dr. Martin Fuss is Chief Medical Officer and the Executive Director of the Clinical Cooperative Think Tank (C2T2) as well as a practicing radiation oncologist and partner in Radiation Oncology Specialists in Tualatin, OR. Dr. Fuss graduated from medical school at the University of Heidelberg, Germany where he also obtained his doctorate degree in human imaging assessing blood flow changes in the brain using functional MRI techniques (DCE-MRI). He underwent his specialty training in radiation oncology at the University of Heidelberg and at the German Cancer Research Center (dkfz). During his residency, he was invited as a research fellow at the Proton Radiation Therapy facility at Loma Linda University Medical Center in Loma Linda, CA. From 2000 to 2006 he was a faculty member at The University of Texas Health Science Center at San Antonio, San Antonio, TX (UTHSCSA). Prior to moving into private practice, he was Professor and Vice Chair of the Department of Radiation Medicine at Oregon Health & Science University (OHSU) from 2006-2013.

Mark Arnold

Senior Vice President of Marketing

Mr. Arnold comes to ViewRay with nearly 20 years marketing experience within the oncology life sciences field. As former Vice President of Global Marketing at Elekta, Mr. Arnold led the commercialization efforts for the linear accelerator, oncology information system and treatment planning software businesses. Mr. Arnold also held the position of Senior Director of Marketing at Accuray Incorporated, overseeing product management, product marketing and marketing communications responsibilities for the CyberKnife® product portfolio.

A New Kind of Medical Technology Company

ViewRay was founded on the belief that enhanced real-time visualization combined with on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients.

MRI-guided radiation therapy was conceived by company founder James F. Dempsey, PhD, while he was a member of the radiation oncology faculty at the University of Florida in 2004. And ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies.

In Brief

Founded: 2004
Headquarters: Cleveland, Ohio
Corporate status: Publicly held
Market: Radiation therapy and imaging technologies

Board of Directors

Scientific Advisory Board

John Bayouth, PhD, University of Wisconsin, Madison
Jeffrey Bradley, MD, Washington University, St. Louis, Missouri
Jürgen Debus, Prof. Dr., NCT Heidelberg, Germany
Carlos A. Perez, MD, Washington University, St. Louis, Missouri

Michael Steinberg, MD, University of California, Los Angeles
Vincenzo Valentini, MD, Universita Cattolica S. Cuore Roma
Hong-Gyun Wu, MD, Seoul National University Hospital, Seoul,South Korea

Contact Us

MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. Over 3000 treatments have been delivered at centers world-wide since 2011.

Contact us to learn more about how we are making the invisible, visible every day across the world.

Contact Us

  Global Info


Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy